This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

Oncology Congresses
Let's collaborate Boehringer Ingelheim

Oncology Congresses

Boehringer Ingelheim is committed to addressing some of society’s most challenging healthcare issues. We want to share our knowledge and encourage clinical advances, which is why we maintain a presence at key congresses including ASCO, ELCC, WCLC and ESMO. Find out more about our activities at the following oncology congresses.

ESMO 2019 Congress

Find information on Boehringer Ingelheim’s activities at ESMO 2019

WCLC 2019

Find information on Boehringer Ingelheim’s activities at WCLC 2019

ASCO 2019

Find information on Boehringer Ingelheim’s activities at the ASCO 2019

ELCC 2019

Find information on Boehringer Ingelheim’s activities at ELCC 2019

AACR 2019

Find information on Boehringer Ingelheim’s activities at AACR 2019.

ESMO Asia 2018

Find information on Boehringer Ingelheim’s activities at ESMO Asia 2018.

CSCO 2018

Find information on afatinib clinical data, and Boehringer Ingelheim’s activities at CSCO 2018. This website is intended for HCPs outside the US and the UK.

Related information

About afatinib

A detailed look at afatinib’s mechanism of action and the ErbB Family of receptors that are targeted by afatinib

About nintedanib

A detailed look at nintedanib’s mechanism of action and the role of angiogenesis in cancer
Back to top

* Afatinib is approved in more than 80 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.

**Nintedanib is being investigated in malignant pleural mesothelioma (MPM) and is not approved for this use. The efficacy and safety of nintedanib in MPM have not been established.

© 2018 Boehringer Ingelheim International GmbH. All rights reserved.

Last updated: May 2018